



Ref: OPL/Share/2019/60
April 30, 2019

Managing Director
Dhaka Stock Exchange Ltd
9/F Motijheel C/A
Dhaka-1000.

Subject : Price Sensitive Information.

Dear Sir,

As per rule no. 33 of the DSE Listing Regulations, 2015, the Board of Directors of **Orion Pharma Limited** has adopted its **un-audited 3rd quarterly financial statements** in its Board Meeting held Today on April 30, 2019 at 5:15 pm in the registered office at Orion House, 153-154, Tejgaon I/A, Dhaka-1208. The following decisions were taken in the meeting :

	March 31, 2019		June 30, 2018	
Consolidated NAV per Share - Q3 (Including Revaluation Surplus)	BDT. 74.29		BDT. 72.88	
Consolidated NAV per Share - Q3 (Excluding Revaluation Surplus)	BDT. 66.05		BDT. 64.55	
	July 01, 2018 to March 31, 2019	July 01, 2017 to March 31, 2018	Jan 01, 2019 to March 31, 2019	Jan 01, 2018 to March 31, 2018
Consolidated Earnings Per Share (EPS)- Q3	BDT. 3.01	BDT. 2.76	BDT. 0.95	BDT. 0.69
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	BDT. 7.15	BDT. 8.57	-----	-----

Please acknowledge the receipt.

Thanking you,

Sincerely yours'

Md. Ferdous Jaman
Company Secretary